Cheng-Ying Ho, MD, PhD; Mohammad Salimian, MD; Julia Hegert, MD; et al.
free access
has active quiz
has audio
JAMA Neurol. 2022;79(6):544-553. doi:10.1001/jamaneurol.2022.0154
This cohort study evaluates the association of COVID-19 infection with olfactory bulb by performing an ultrastructural and histopathological analysis of patients with COVID-19 and age- and disease severity–compatible controls.
-
Audio Author Interview:
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19
Kelly G. Knupp, MD, MSCS; Ingrid E. Scheffer, PhD, MBBS; Berten Ceulemans, MD, PhD; et al.
open access
JAMA Neurol. 2022;79(6):554-564. doi:10.1001/jamaneurol.2022.0829
This randomized clinical trial examines the change from baseline in drop seizure frequency, response rates, and improvement on the Clinical Global Impression scale among patients with Lennox-Gastaut syndrome.
Michael S. Rafii, MD, PhD; Olivier Sol, MD; William C. Mobley, MD, PhD; et al.
JAMA Neurol. 2022;79(6):565-574. doi:10.1001/jamaneurol.2022.0983
This phase 1b randomized clinical trial assesses the safety and tolerability of the antiamyloid ACI-24 vaccine and investigates the vaccine’s ability to induce immunogenicity among adults with Down syndrome at risk of developing a genetic form of Alzheimer disease.
Ryosuke Oki, MD; Yuishin Izumi, MD, PhD; Koji Fujita, MD, PhD; et al.
JAMA Neurol. 2022;79(6):575-583. doi:10.1001/jamaneurol.2022.0901
This randomized clinical trial showed that use of ultrahigh-dose methylcobalamin in Japanese patients in the early stages of amyotrophic lateral sclerosis with moderate progression can slow functional decline and had a good safety profile.
Roch A. Nianogo, MD, PhD; Amy Rosenwohl-Mack, RN, MS; Kristine Yaffe, MD; et al.
JAMA Neurol. 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976
This cross-sectional study evaluates modifiable risk factors associated with Alzheimer disease and related dementias in the US and assesses risk differences by sex and race and ethnicity.
Christina B. Young, PhD; Joseph R. Winer, PhD; Kyan Younes, MD; et al.
JAMA Neurol. 2022;79(6):592-603. doi:10.1001/jamaneurol.2022.0676
This cross-sectional study evaluates the prevalence of cortical tau positron emission tomography heterogeneity in a large cohort of clinically unimpaired older adults with elevated β-amyloid.
Lars Egil Roberg, MD; Olav Monsson, MD; Simon Bang Kristensen, PhD; et al.
JAMA Neurol. 2022;79(6):604-613. doi:10.1001/jamaneurol.2022.0609
This cohort study uses a new 3-factor scoring system to estimate long-term outcomes in patients who experienced status epilepticus.
Maurice Abou Jaoude, MS; Claire S. Jacobs, MD, PhD; Rani A. Sarkis, MD, MSc; et al.
JAMA Neurol. 2022;79(6):614-622. doi:10.1001/jamaneurol.2022.0888
This diagnostic study investigates whether a computer algorithm can be trained to detect hippocampal epileptiform activity on scalp electroencephalogram without the need for intracranial electrodes.